Positive News SentimentPositive NewsNASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free VYNE Stock Alerts $2.59 +0.01 (+0.39%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$2.50▼$2.6250-Day Range$2.18▼$3.1052-Week Range$1.67▼$6.79Volume17,088 shsAverage Volume38,047 shsMarket Capitalization$37.63 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get VYNE Therapeutics alerts: Email Address VYNE Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.0% Upside$5.75 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.59Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.56 out of 5 starsMedical Sector281st out of 931 stocksPharmaceutical Preparations Industry125th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VYNE Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.46% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently decreased by 30.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VYNE. Previous Next 3.7 News and Social Media Coverage News SentimentVYNE Therapeutics has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for VYNE Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for VYNE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VYNE Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for VYNE Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VYNE Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… About VYNE Therapeutics Stock (NASDAQ:VYNE)VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Read More VYNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNE Stock News HeadlinesMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline ProgressionMay 9, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical PipelineMay 9, 2024 | investorplace.comVYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comVYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comVYNE Therapeutics receives FDA approval for trial of VYN202May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical DataMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amidst Favorable IND Clearance and Promising VYN202 DevelopmentMay 6, 2024 | globenewswire.comVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET InhibitorMay 1, 2024 | globenewswire.comVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual MeetingApril 13, 2024 | finance.yahoo.comVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansMarch 19, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2024 | globenewswire.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 7, 2024 | seekingalpha.comWall Street Breakfast Podcast: NYCB Gets $1B Investment BoostMarch 3, 2024 | finance.yahoo.comVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 29, 2024 | markets.businessinsider.comBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical DevelopmentsFebruary 29, 2024 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateFebruary 27, 2024 | finance.yahoo.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 27, 2024 | globenewswire.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 21, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | globenewswire.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 2, 2024 | finance.yahoo.comFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired StockJanuary 10, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial ResultsJanuary 3, 2024 | finance.yahoo.comVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsNovember 20, 2023 | msn.comVYNE Therapeutics says director Lepore buys 13K shares in coSee More Headlines Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/29/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VYNE CUSIPN/A CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$5.75 High Stock Price Target$5.75 Low Stock Price Target$5.75 Potential Upside/Downside+122.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,450,000.00 Net Margins-6,874.47% Pretax Margin-6,737.83% Return on Equity-56.75% Return on Assets-48.81% Debt Debt-to-Equity RatioN/A Current Ratio13.02 Quick Ratio13.02 Sales & Book Value Annual Sales$420,000.00 Price / Sales89.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.41Miscellaneous Outstanding Shares14,530,000Free Float14,266,000Market Cap$37.63 million OptionableNot Optionable Beta1.26 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Comp: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Comp: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Comp: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel FAAD (Age 73)M.D., Consultant Comp: $40.2kKey CompetitorsNextCureNASDAQ:NXTCKezar Life SciencesNASDAQ:KZRMediciNovaNASDAQ:MNOVHookipa PharmaNASDAQ:HOOKParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 16,199 shares on 5/20/2024Ownership: 0.112%Patrick G LeporeBought 13,000 shares on 11/15/2023Total: $50,830.00 ($3.91/share)View All Insider TransactionsView All Institutional Transactions VYNE Stock Analysis - Frequently Asked Questions Should I buy or sell VYNE Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNE shares. View VYNE analyst ratings or view top-rated stocks. What is VYNE Therapeutics' stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for VYNE Therapeutics' shares. Their VYNE share price targets range from $5.75 to $5.75. On average, they predict the company's share price to reach $5.75 in the next year. This suggests a possible upside of 122.0% from the stock's current price. View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts. How have VYNE shares performed in 2024? VYNE Therapeutics' stock was trading at $2.33 on January 1st, 2024. Since then, VYNE stock has increased by 11.2% and is now trading at $2.5901. View the best growth stocks for 2024 here. Are investors shorting VYNE Therapeutics? VYNE Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 57,400 shares, a drop of 30.0% from the April 30th total of 82,000 shares. Based on an average daily trading volume, of 94,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the company's stock are sold short. View VYNE Therapeutics' Short Interest. When is VYNE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our VYNE earnings forecast. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its quarterly earnings data on Thursday, February, 29th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.30. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative trailing twelve-month return on equity of 56.75% and a negative net margin of 6,874.47%. When did VYNE Therapeutics' stock split? VYNE Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS). Who are VYNE Therapeutics' major shareholders? VYNE Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.11%). Insiders that own company stock include Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYNE) was last updated on 5/29/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.